REFERENCES
- Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997; 349:1294.
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
- Selik RM, Karon JM, Ward JW. Effect of the human im-munodeficiency virus epidemic on mortality from opportu-nistic infections in the United States in 1993. J Infect Dis. 1997;176: 632–636.
- Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimi-crob Chemother 2006;58:235–242.
- Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immuno-deficiency virus-infected adults. Antimicrob Agents Che-mother 2001;45: 2733–2739.
- Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clini-cal pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41–66.
- Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PM PA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimi-crob Agents Chemother 1998;42: 612–617.
- Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 200216: 1257–1263.
- Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N En al J Med. 2002;346:2039–2046.
- Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002185: 599–607.
- Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–272.
- Declaration of Helsinki. Recommendations guiding physi-cians in biomedical research involving human subjects. In: 52nd World Medical Association General Assembly; 2000; Edinburgh, Scotland.
- Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence in-struments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clini-cal Trials Group (AACTG). AIDS Care. 2000;12:255–266.
- Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin EpidemioL 2001;54\(suppl 1):577–590.
- la Porte CJ, Schippers EF, van der Ende ME, et al. Phar-macokinetics of once-daily lopinavir/ritonavir and the influ-ence of dose modifications. AIDS. 2005;19:1105–1107.
- Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-phar-macodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodefi-ciency virus-infected patients. Antimicrob Agents Che-mother 2003;47:350–359.
- van Heeswijk RP, Bourbeau M, Seguin I, et al. Absence of circadian variation in the pharmacokinetics of lopinavir/ ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin PharmacoL 2005;59:398–404.
- Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006;43:153–160.
- Gatti G, Di BA, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083–2089.
- Breilh D, Rouzes A, Djabarouti S, et al. Pharmacokinetic drug interaction of lopinavir/rotinavir in combination with tenofovir in experienced HIV+ patients. In: Program and abstracts of the 44th Interscience Conference on Antimi-crobial Agents and Chemotherapy; 2004; Washington, DC. Abstract A–445.